[
  {
    "ts": "2025-12-29T13:42:39+00:00",
    "headline": "Should You Be Confident in Vertex Pharmaceuticals Incorporated’s (VRTX) Long-Term Outlook?",
    "summary": "Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be downloaded here. The portfolio underperformed in the quarter due to stock selection. The composite returned 5.02%, net of fees, compared to 7.62% for the MSCI AC […]",
    "url": "https://finance.yahoo.com/news/confident-vertex-pharmaceuticals-incorporated-vrtx-134239591.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a81d90a0-fefb-3dd2-9c93-e4202232954e",
      "content": {
        "id": "a81d90a0-fefb-3dd2-9c93-e4202232954e",
        "contentType": "STORY",
        "title": "Should You Be Confident in Vertex Pharmaceuticals Incorporated’s (VRTX) Long-Term Outlook?",
        "description": "",
        "summary": "Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be downloaded here. The portfolio underperformed in the quarter due to stock selection. The composite returned 5.02%, net of fees, compared to 7.62% for the MSCI AC […]",
        "pubDate": "2025-12-29T13:42:39Z",
        "displayTime": "2025-12-29T13:42:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/73o67FZt31QGX4RW9oCwEA--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eKC281F2zJCXGmB_sO5saA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d61abed3f7567688cd16b4e2785171ec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/confident-vertex-pharmaceuticals-incorporated-vrtx-134239591.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/confident-vertex-pharmaceuticals-incorporated-vrtx-134239591.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]